WRAPSODY CIE Restoring the Lifeline: The Carlos Lima Story
Vascular access is a lifeline. Keeping it open for patients like Carlos is our priority. After 15 months of repeated failures, Carlos found a durable solution with WRAPSODY® CIE.
Please Note: The product described on this page is for sale and use in the United States only. You can find the European-approved Merit WRAPSODY here.
“I spent 15 months going back to the clinic every month. I thought my access was gone.” — Carlos Lima
For patients like Carlos, WRAPSODY CIE is designed to end the cycle of repeated clinic visits and restore long-term stability.
Other stents treat the moment. WRAPSODY cares for what comes next.
A cell‑impermeable design supports long‑term vessel patency, reducing unplanned access reinterventions. Softened end rows further minimize vessel trauma. Together, these advances help patients experience fewer dialysis disruptions, giving them more time to enjoy life between procedures.
There are plenty of covered stents. There’s only one with gentle edges.
The softened end rows of the WRAPSODY CIE are engineered with less radial force and are designed to better conform to healthy vessel tissue and prevent the ‘edge effect’ trauma that leading covered stents can cause.1
Designed to reduce fibrin deposition and thrombus formation without the use of coatings or drugs.1
2. Cell-impermeable middle layer
Specifically designed to prevent transmural cellular migration.2
3. Biocompatible ePTFE outer layer
Designed to allow tissue ingrowth to secure the device and prevent endoprosthesis migration.
“The six-month efficacy data is compelling and provides clinicians the chance to evaluate how WRAPSODY can help us prolong the vascular access of our patients. WRAPSODY should be the new standard of care for these patients.”
– Mahmood K. Razavi, MD, FSIR, FSVM, Interventional Radiologist and Medical Director of Clinical Research at St. Joseph Heart and Vascular Center in Orange, Calif., and Co-Principal Investigator of the WAVE trial.
More Time to Enjoy Life Instead of More Time in Procedures.
Speak With a Rep
If you’d like more information on any of Merit’s products or how we can partner with you to improve your workflows, please fill out the form below. A rep will be in touch shortly.
"*" indicates required fields
Patency rates are defined differently; data comes from different individual studies and may differ in a head-to-head comparison, and therefore may not be predictive of clinical results.
REFERENCES
1. Data on file.
2. Dolmatch et al. 2020. “Evaluation of a Novel Spun Polytetrafluoroethylene Stent Graft in an Ovine External Iliac Artery Model.” Journal of Vascular and Interventional Radiology 21, no. 3 (March): 494-502. doi.org10.1016/j.jvir.2019.07.036. (PMID: 31959517)
3. Razavi. “Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY® Arteriovenous Access Efficacy (WAVE) trial”. PowerPoint presented at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scientific symposium, Lisbon, Portugal, September, 2024.
4. Razavi. “Six-month safety and efficacy outcomes from the WRAPSODY® Arteriovenous Access Efficacy (WAVE) trial”. PowerPoint presented at the annual VEITH symposium, November, 2024.
